- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00521560
A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas (escZ-BEAM)
Phase I/II Study Concomitant High-Dose Radio-Immuno- and Chemotherapy With Simultaneous Application of Zevalin and BEAM Followed by Autologous Peripheral Stem Cell Transplantation in Relapsed and Refractory CD 20+ Non-Hodgkin's Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Göttingen, Germany, 37075
- Institut für anwendungsorientierte Forschung und klinische Studien (IFS GmbH)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 18 - 65 years
- Risk group: 1) Progression on primary therapy 2) Initial or subsequent relapse
- Histology: Diagnosis of relapsed aggressive non-Hodgkin lymphoma, whenever possible confirmed by an excision biopsy of a lymph node or by a sufficiently large biopsy of an extranodal site if no lymph node lesion is present. The expression of the CD20 antigen must be demonstrated in the primary lesion or in the relapse. Specifically, the following entities can be treated in this study:
B-NHL:
Grade III B follicular lymphoma Diffuse B-cell lymphoma centroblastic immunoblastic plasmoblastic anaplastic-large-cell T-cell rich B-cell lymphoma Primary effusion lymphoma Intravascular B-cell lymphoma Primary mediastinal B-cell lymphoma Mantle cell lymphoma, blastoid Variants of Burkitt's lymphoma Aggressive marginal zone lymphoma (monocytoid)
- General condition: General condition ECOG 0-3 (Karnofsky: 40 - 100 %); for definition see Annex 14.10
- Presence of declaration of participation of the center and the patient's written consent form
Exclusion Criteria:
- Prior mediastinal or extensive abdominal irradiation
- Prior high-dose therapy and autologous stem cell transplantation
- Impairment of renal function (creatinine > 2.5 mg/dL, creatinine clearance < 20 mL/min)
- Impairment of hepatic function (bilirubin > 2.0 mg/dL, cholinesterase [CHE] < 2000 U/L)
- Impairment of pulmonary function (transfer lung factor for CO [TLCO] < 50 %, forced expiratory volume in 1 sec [FEV1] < 60 %, vital capacity [VC] < 60 %)
- Relevant deterioration of the above organ functions on salvage therapy
- Failure of stem cell mobilization
- Active viral hepatitis
- HIV infection
- Other active or not conclusively curatively treated malignoma
- Severe concomitant psychiatric illness or suspected lack of patient compliance
- Pregnancy or unreliable contraception
- Highly dynamic progress of lymphoma (lactate dehydrogenase [LDH] > 1.5 x upper limit of normal [ULN]) after salvage therapy immediately prior to radioimmunotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5), respectively. High dose therapy will be given as BEAM
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary outcome variable is the highest achievable dose level of 90Y-Zevalin administered immediately before BEAM high-dose therapy and followed by autologous stem cell transplantation.
Time Frame: 3 Year
|
3 Year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Treatment related mortality (TRM), freedom from progression (FFP), Survival (OS), progression free survival (PFS) grade III -IV toxicity (CTC) on lung, liver and kidney
Time Frame: 3 Years
|
3 Years
|
Collaborators and Investigators
Investigators
- Study Director: Bertram Glass, Prof. Dr., German Society of Cancer e.V.
- Principal Investigator: Martin Gramatzki, MD PhD, Städtisches Krankenhaus Kiel, II. Med. Uniklinik, Kiel, Germany
- Principal Investigator: Mattias Witzens Harig, MD PhD, Abteilung Innere Medizin V, Hämatologie, Onkologie, Heidelberg, Germany
- Principal Investigator: Bernd Hertenstein, MD PhD, Klinikum Bremen-Mitte gGmbH, Medizinische Klinik I, Bremen, Germany
- Principal Investigator: Georg Heß, MD PhD, III Med., Schwerpunkt Hämatologie / Onkologie, Mainz, Germany
- Principal Investigator: Dorothea Kofahl-Krause, MD PhD, MHH, Hämatologie, Hämostaseologie und Onkologie, Hannover, Germany
- Principal Investigator: Norbert Schmitz, MD PhD, Asklepios Klinik St. Georg, Hämatologische Abt., Hamburg, Germany
- Principal Investigator: Jörg Schubert, MD PhD, Universitätskliniken d. Saarlandes, Med. I, Homburg/Saar, Germany
- Principal Investigator: Lutz Uharek Uharek, MD PhD, Charité - Campus Benjamin Franklin, Med. III, Berlin, Germany
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DSHNHL 2004-R4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Non-Hodgkin-Lymphoma
-
John ReneauActive, not recruitingRecurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Walter HanelRecruitingRecurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Refractory Anaplastic Large Cell Lymphoma | T-Cell Non-Hodgkin Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)SuspendedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Breast Carcinoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Breast Cancer AJCC v6 and v7 | Breast Adenocarcinoma and other conditionsUnited States
-
John ReneauRecruitingRecurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Adult T-Cell Leukemia/LymphomaUnited States
-
City of Hope Medical CenterWithdrawnSezary Syndrome | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Mycosis Fungoides | Folliculotropic Mycosis Fungoides | CD30-Positive Neoplastic Cells Present | Refractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaUnited States
-
David Bond, MDBristol-Myers SquibbActive, not recruitingDiffuse Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | Transformed Non-Hodgkin Lymphoma | Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage... and other conditionsUnited States
-
Case Comprehensive Cancer CenterTerminatedPrimary Central Nervous System Non-Hodgkin LymphomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent... and other conditionsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
Clinical Trials on Zevalin
-
Lymphoma Study AssociationCompletedB-Cell LymphomaFrance, Belgium, Switzerland
-
Soroka University Medical CenterUnknown
-
Chulalongkorn UniversityBayerTerminatedDiffuse Large B-cell LymphomaThailand
-
BayerCompletedNon-Hodgkin's Lymphoma (NHL)Japan
-
Spectrum Pharmaceuticals, IncTerminatedDiffuse Large B-cell Lymphoma | Follicle Center LymphomaUnited States, France, United Kingdom, Ireland, Israel, Belgium, Spain, Netherlands, Australia, Puerto Rico, Canada, Italy, Austria
-
Spectrum Pharmaceuticals, IncBayerCompleted
-
BayerCompletedLymphoma, Follicular | Non-Hodgkin LymphomaBelgium
-
A.O. Ospedale Papa Giovanni XXIIIRegional Hospital of BolzanoTerminatedLymphoma, Non-HodgkinItaly
-
Tufts Medical CenterSpectrum Pharmaceuticals, IncTerminatedMultiple MyelomaUnited States
-
University Hospital, BordeauxBayerCompletedDiffuse Large B-Cell Lymphoma | Mantle Cell LymphomaFrance